0000000000681589

AUTHOR

Kamal Sharma

0000-0001-5866-2566

showing 1 related works from this author

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

2021

Abstract Introduction Although the COVID‐19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. Objective To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID‐19 vaccines. And to identify on whether COVID‐19 vaccine has temporal relationship between development of herpes zoster (HZ). Methods We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like “Shingles,” “Herpes zoster,” “Varicella zoster,” “COVID‐19,” “Vaccine,” “SARS‐CoV‐2.” No filters including country of publication, language…

MalePediatricsmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)herpes zosterReview ArticleDermatologyMalignancyCovidVaricella zosterChickenpoxCOVID‐19vaccinemedicineHerpes Zoster VaccineHumansAdverse effectSARS-CoV-2business.industryIncidence (epidemiology)Metabolic disorderCOVID-19Middle Agedmedicine.diseaseVaccinationFemalebusinessShinglesJournal of Cosmetic Dermatology
researchProduct